ApprovedFDA approval

Lisraya (brepocitinib)

Priovant Therapeutics

Marketer take

An oral treatment for dermatomyositis, a condition with few approved options (IVIG is one), so rheumatology and dermatology teams will need education on diagnosis and where an oral therapy fits.

Sponsor company
Priovant Therapeutics
Indication
To treat dermatomyositis in adults
Therapeutic area
Immunology, Dermatology
Event
FDA approval
Date
Aug 27, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move